Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175681 | 0.80 | PPARD (0.50) | GAATDP1L3MBTL1HPGDLMNA | |
| SCHEMBL175736 | 0.76 | YWHAG (0.53) | GAAADRB2TDP1HPGDLMNA | |
| SCHEMBL11212981 | 0.74 | PDK2 (0.45) | GAAADRB2TDP1NPC1HPGD | |
| SCHEMBL175651 | 0.73 | APP (0.57) | GAAADRB2TDP1LMNAALOX5 | |
| SCHEMBL11527161 | 0.73 | GAA (0.55) | GAAATMTDP1NPC1L3MBTL1 | |
| SCHEMBL23558749 | 0.72 | GAA (0.45) | GAAATMTDP1NPC1L3MBTL1 | |
| SCHEMBL17779423 | 0.72 | HPGD (0.40) | GAAATMADRB2L3MBTL1HPGD | |
| SCHEMBL4019934 | 0.72 | PTPN7 (0.59) | L3MBTL1LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL16270511 | 0.72 | GAA (0.59) | GAAATMTDP1NPC1L3MBTL1 | |
| SCHEMBL27513734 | 0.72 | ALOX15 (0.48) | GAATDP1HPGDLMNAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-8227643-B2 | Sirtuin 1 and the treatment of neurodegenerative diseases | PROTEOTECH, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | PROTAMED, INC. | 2012-03-08 | — | — | US | claimed |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2011-06-16 | — | — | US | claimed |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | PROTEOTECH INC. | 2011-01-20 | — | — | US | claimed |
| US-7714170-B2 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-7601876-B2 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTEOTECH, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTAMED, INC. | 2009-06-04 | — | — | US | claimed |
| WO-2009017848-A9 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2009017848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008154083-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | PROTEO TECH INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | claimed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | claimed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | claimed |
| EP-1751097-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2005113489-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTAMED, INC. | 2004-07-01 | — | — | US | claimed |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTAMED INC (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2003101927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTEOTECH, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | IAPP, SNCA, IDE | GAA 178/4885ATM 2254/4885ADRB2 285/4885 |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | GAA 386/4885ATM 213/4885ADRB2 4609/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | GAA 46/4885ATM 2482/4885ADRB2 153/4885 |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | NR1H2, NR1H3, MSR1 | GAA 3592/4885ATM 4453/4885ADRB2 295/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | GAA 4137/4885ATM 3612/4885ADRB2 287/4885 |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | GAA 386/4885ATM 213/4885ADRB2 4609/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | GAA 58/4885ATM 2565/4885ADRB2 152/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | GAA 18/4885ATM 2357/4885ADRB2 547/4885 |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | APP, BACE1, BACE2 | GAA 52/4885ATM 2254/4885ADRB2 450/4885 |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | SIRT1, SIRT3, SIRT2 | GAA 1005/4885ATM 1095/4885ADRB2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.